Perindopril 2mg/indapamide 0.625mg - Fixed low-dose combination

Low-dose drug combinations have been proposed in International Guidelines f or use in patients with hypertension. The fixed low-dose combination of per indopril 2mg with indapamide 0.625mg combines an angiotensin converting enz yme (ACE) inhibitor with a non-thiazide diuretic. Coadministration of perindopril and indapamide did not have any clinically significant effects on the pharmacokinetic profile of either agent in healt hy volunteers. In experimental models of hypertension, perindopril/indapamide restored end othelial function, improved microvascular density, reduced left ventricular and aortic hypertrophy, and reversed renal end-organ damage. Once daily oral perindopril 2mg/indapamide 0.625mg normalised blood pressur e (BP) in 83.6% of elderly patients with essential hypertension (diastolic BP was reduced to less than or equal to 90mm Hg) and 81.7% of those with is olated systolic hypertension (systolic BP was reduced to <160mm Hg) after a pproximate to 1 year of treatment. BP normalisation was sustained in 79.8% of patients throughout the study. Fixed low-dose perindopril/indapamide had a tolerability profile similar to that of placebo in clinical trials; most adverse events were of mild to mo derate severity. Coadministration of the 2 agents reduced the incidence of hypokalaemia seen with indapamide alone.